“…Such drugs would likely be active against all current drug-resistant viral strains, because the RNase H active site is located at the opposite end of the enzyme from the polymerase domain (ϳ50 Å away) that is currently targeted by nucleoside and nonnucleoside RT inhibitors (79). Several compounds have been found in recent years to effectively inhibit the RNase H activity of HIV-1 RT, including ␣,␥-diketo acids and derivatives (27,77,78,91), pyrimidinol carboxylic acids (43,47), hydroxytropolones (including -thujaplicinol) (6,12,15,21,34), dimeric lactones (19), 1,3,4,5-tetragalloylapiitol (86), phenolic glycosides (10), vinylogous ureas (16,94), N-hydroxyimides (33,44), 2-hydroxyisoquinoline-1,3(2H,4H)-diones (8,9), acylhydrazones (11,30,35,80), and naphthyridinones (84,95). Although these inhibitors have been studied for the ability to inhibit HIV-1 RT, little is known about their effectiveness against other retroviral RTs, such as the gammaretroviral Moloney murine leukemia virus (MoMLV) and xenotropic murine leukemia virus-related virus (XMRV) RTs.…”